Alector, Inc. — Investor Relations & Filings

Alector, Inc. is a clinical-stage biotechnology company that develops therapies for neurodegenerative diseases. The company pioneers an approach known as immuno-neurology, which utilizes the body's immune system to address brain disorders. By integrating insights from human genetics, neuroscience, and immunology, Alector is advancing a pipeline of potential first-in-class and best-in-class medicines. Its therapeutic candidates are designed to treat conditions such as Alzheimer's disease and frontotemporal dementia by removing toxic proteins, replacing deficient proteins, and restoring the function of immune and nerve cells. The company's primary mission is to slow the progression of neurodegenerative diseases and improve overall brain health.